GE HealthCare to Acquire SOFIE Biosciences for $945 Million

GE HealthCare entered into a definitive agreement to acquire SOFIE Biosciences from Trilantic North America for $945 million in cash. SOFIE, a U.S. contract manufacturer of PET radiopharmaceuticals, will expand GE HealthCare’s U.S. manufacturing and distribution network; the transaction is expected to close in the first half of 2027, subject to regulatory approvals and other closing conditions.